Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic-Guided Reduction of Emicizumab in Patients with Congenital Hemophilia a in the Netherlands: Interim Analysis from the Dosemi Study

Konrad Van Der Zwet, Marjon H. Cnossen, Floor CJI Moenen, Saskia EM Schols, Paula F Ypma, Paul L. den Exter, Louise Hooimeijer, Michiel Coppens, Ron A.A. Mathôt, Anouk A.M.T. Donners, Alexander Janssen, Ilmar Kruis, Eduard J. Van Beers, Corien L. Eckhardt, Rolf T. Urbanus, Lize Fie Ditteke Van Vulpen, Roger EG Schutgens, Kathelijn Fischer

Blood (2024) 144 (Supplement 1): 127.

https://doi.org/10.1182/blood-2024-193995

Published: 2024

Journal Articles

Evaluating the Clinical Relevance of Thrombin Generation Potential during Emicizumab Therapy

Konrad Van Der Zwet, Mark Roest, Dana Huskens, Eduard J. Van Beers, Kathelijn Fischer, Lize Fie Ditteke Van Vulpen, Roger EG Schutgens, Rolf T. Urbanus

Blood (2024) 144 (Supplement 1): 3960.

https://doi.org/10.1182/blood-2024-204587

Published: 2024

Journal Articles

Efficacy of Efanesoctocog Alfa on Physical Functioning: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A

Amanda Wilson, Nana Kragh, Jennifer Dumont, Jerome Mshijid, Annemieke Willemze, Linda Bystricka, Chuanwu Zhang, Angela C. Weyand, Kathelijn Fischer, Victor Jimenez-Yuste

Blood (2022) 140 (Supplement 1): 5595–5596.

https://doi.org/10.1182/blood-2022-167542

Published: 2022

Journal Articles

The Emicizumab Switch: Real-World Data of 251 Pediatric Patients from the Pednet Registry

Konrad Van Der Zwet, Marloes de Kovel, Jayashree Motwani, Christel Van Geet, Beatrice Nolan, Heidi Glosli, Gili Kenet, Kathelijn Fischer

Blood (2022) 140 (Supplement 1): 8442–8443.

https://doi.org/10.1182/blood-2022-162181

Published: 2022

Journal Articles

Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database

Olav Versloot, MSc, Emma Iserman, Pierre Chelle, PhD, Federico Germini, MD MSc, Tushara Mathew, Alfonso Iorio, MDPhD, Kathelijn Fischer

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-142816

Published: 2020

Journal Articles

Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments

Olav Versloot, MSc, Emma Iserman, Pierre Chelle, PhD, Federico Germini, MD MSc, Tushara Mathew, Alfonso Iorio, MDPhD, Kathelijn Fischer

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141801

Published: 2020

Journal Articles

BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study

Sanjay Ahuja, MD, Kathelijn Fischer, Tina Biss, Monika Maas Enriquez, Maria-Elisa Mancuso, MacGregor Steele, MD FRCPC, Maria Wang, Gili Kenet

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-140303

Published: 2020

Journal Articles

Interim Analysis of the Extension Study with rVIII-SingleChain in Previously Untreated Patients (PUPs) with Severe Hemophilia A (CSL627-3001)

Elena Santagostino, Kathelijn Fischer, Christoph Koenigs, MD PhD, Claudia Djambas Khayat, MD BSc, Samantha Lucas, Blanca Salazar, Andres Brainsky, MD, Thomas Chung, Brahm Goldstein, Johnny Mahlangu, MMed, FCPath

Blood (2019) 134 (Supplement_1): 162.

https://doi.org/10.1182/blood-2019-123981

Published: 2019

Journal Articles

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A

H. Marijke van den Berg, Kathelijn Fischer, Manuel Carcao, Hervé Chambost, Gili Kenet, Karin Kurnik, Chris Königs, Christoph Male, Elena Santagostino, Rolf Ljung

Blood (2019) 134 (3): 317–320.

https://doi.org/10.1182/blood.2019000658

Published: 2019

Includes: Supplemental data

Journal Articles

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

Blood (2018) 132 (Supplement 1): 2472.

https://doi.org/10.1182/blood-2018-99-114518

Published: 2018

Journal Articles

B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B

Margaret Ragni, Roshni Kulkarni, K. John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Kathelijn Fischer, Johnny Mahlangu, Amy Shapiro, Beatrice Nolan, Johannes Oldenburg, Tadashi Matsushita, Annemieke Willemze, Huixing Yuan, Dan Rudin

Blood (2018) 132 (Supplement 1): 1214.

https://doi.org/10.1182/blood-2018-99-110100

Published: 2018

Journal Articles

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Blood (2016) 128 (22): 3774.

https://doi.org/10.1182/blood.V128.22.3774.3774

Published: 2016

Journal Articles

Clinical Joint Outcome after Joint Bleeds in Patients with Von Willebrand Disease Is Comparable to Moderate and Severe Hemophilia A Despite Fewer Joint Bleeds

Karin PM van Galen, MD, Merel Timmer, Mrs., Piet de Kleijn, Mr., Frank W.G. Leebeek, MD PhD, Roger E.G. Schutgens, MD PhD, Kathelijn Fischer, Eveline Mauser-Bunschoten

Blood (2016) 128 (22): 3789.

https://doi.org/10.1182/blood.V128.22.3789.3789

Published: 2016

Journal Articles

Long Term Safety and Efficacy of Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis in Children with Hemophilia B: Interim Results of the B-Yond Extension Study

Jonathan M. Ducore, Kathelijn Fischer, Roshni Kulkarni, MD, Beatrice Nolan, Carolyn M. Bennett, David J Perry, Huixing Yuan, Alejandra Ramirez-Santiago, Francesca Ferrante, Stefan Lethagen

Blood (2016) 128 (22): 4976.

https://doi.org/10.1182/blood.V128.22.4976.4976

Published: 2016

Journal Articles

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

Kathelijn Fischer, MD PhD MSc, Pratima Chowdary, FRCPath, MRCPath, MRCP, MD, Peter Collins, MD, Amy Cotterill, PhD, Barbara Konkle, MD, Victor S. Blanchette, FRCP, FRCPC, Steven W. Pipe, MD, Martin Wolfsegger, Cstat (RSS), Werner Engl, PhD Cstat, Jimena V Goldstine, PhD, Leonard A. Valentino, MD FAAP, Gerald Spotts, PhD

Blood (2016) 128 (22): 2576.

https://doi.org/10.1182/blood.V128.22.2576.2576

Published: 2016

Journal Articles

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Blood (2016) 128 (5): 630–637.

https://doi.org/10.1182/blood-2016-01-687434

Published: 2016

Includes: Supplemental data

Journal Articles

Clinical Outcomes in Children with Hemophilia B Treated Long Term with rFIXFc: Interim Results of the B-YOND Extension Study

Roshni Kulkarni, Beatrice Nolan, Carolyn M. Bennett, Kathelijn Fischer, David J Perry, Christopher Barnes, Huixing Yuan, Alejandra Ramirez-Santiago, Glenn F Pierce, Baisong Mei

Blood (2015) 126 (23): 1093.

https://doi.org/10.1182/blood.V126.23.1093.1093

Published: 2015

Journal Articles

No Association Between Platelet Function and Hemophilia B Phenotype

Roger E.G. Schutgens, MD PhD, Esther R. van Bladel, MD PhD, Kathelijn Fischer, MD PhD MSC, Mark Roest, PhD, Rolf Urbanus, PhD

Blood (2014) 124 (21): 4994.

https://doi.org/10.1182/blood.V124.21.4994.4994

Published: 2014

Journal Articles

Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates

Menchen Xi, Tamara Navarro-Ruan, MLIS. MD, Sunil Mammen, Victor S. Blanchette, MD FRCPC, Cedric R. Hermans, MD PhD, Massimo Morfini, MD, Peter W. Collins, MD, Kathelijn Fischer, MD PhD MSC, Ellis J. Neufeld, Guy Young, MD, Kaan Kavakli, MD, Paolo Radossi, MD, Amy Dunn, Lehana Thabane, PhD, Alfonso Iorio, MD PhD

Blood (2014) 124 (21): 2818.

https://doi.org/10.1182/blood.V124.21.2818.2818

Published: 2014

Journal Articles

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

Gerald Spotts, PhD, Steven W. Pipe, MD, Erik Berntorp, MD PhD, Peter W. Collins, MD, Victor S. Blanchette, MD FRCPC, Kathelijn Fischer, MD PhD MSC, MyungShin Oh, Leonard A. Valentino, MD FAAP

Blood (2014) 124 (21): 689.

https://doi.org/10.1182/blood.V124.21.689.689

Published: 2014

NARROW

Pharmacokinetic-Guided Reduction of Emicizumab in Patients with Congenital Hemophilia a in the Netherlands: Interim Analysis from the Dosemi Study

Evaluating the Clinical Relevance of Thrombin Generation Potential during Emicizumab Therapy

Efficacy of Efanesoctocog Alfa on Physical Functioning: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A

The Emicizumab Switch: Real-World Data of 251 Pediatric Patients from the Pednet Registry

Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database

Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments

BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study

Interim Analysis of the Extension Study with rVIII-SingleChain in Previously Untreated Patients (PUPs) with Severe Hemophilia A (CSL627-3001)

Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A

99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry

B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B

Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study

Clinical Joint Outcome after Joint Bleeds in Patients with Von Willebrand Disease Is Comparable to Moderate and Severe Hemophilia A Despite Fewer Joint Bleeds

Long Term Safety and Efficacy of Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis in Children with Hemophilia B: Interim Results of the B-Yond Extension Study

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Clinical Outcomes in Children with Hemophilia B Treated Long Term with rFIXFc: Interim Results of the B-YOND Extension Study

No Association Between Platelet Function and Hemophilia B Phenotype

Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only